Cantor Fitzgerald Raises Earnings Estimates for AxoGen

Key Points

• Cantor Fitzgerald raised its FY2025 earnings per share estimate for AxoGen from ($0.06) to ($0.05), indicating improved expectations for the medical equipment provider.
• Canaccord Genuity Group lowered its target price on AxoGen from $26.00 to $24.00 while maintaining a "buy" rating, with the consensus target price currently at $24.50.
• AxoGen's stock has recently seen an increase of 1.3%, trading at $14.26, amidst significant activity from institutional investors boosting their holdings in the company.

AxoGen, Inc. (NASDAQ:AXGN - Free Report) - Analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for shares of AxoGen in a research note issued to investors on Wednesday, August 6th. Cantor Fitzgerald analyst R. Osborn now expects that the medical equipment provider will post earnings per share of ($0.05) for the year, up from their prior forecast of ($0.06). The consensus estimate for AxoGen's current full-year earnings is ($0.29) per share.

Other equities research analysts have also issued reports about the company. Canaccord Genuity Group decreased their price objective on AxoGen from $26.00 to $24.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Wall Street Zen raised AxoGen from a "hold" rating to a "buy" rating in a research note on Saturday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $24.50.

AxoGen Trading Down 1.2%

Shares of NASDAQ:AXGN traded down $0.17 during midday trading on Friday, reaching $13.90. The company had a trading volume of 1,060,864 shares, compared to its average volume of 1,836,408. The company has a debt-to-equity ratio of 0.59, a quick ratio of 2.65 and a current ratio of 4.14. AxoGen has a 1-year low of $9.22 and a 1-year high of $21.00. The firm has a market cap of $639.54 million, a price-to-earnings ratio of -138.99 and a beta of 1.00. The company has a fifty day simple moving average of $11.48 and a two-hundred day simple moving average of $14.69.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. State of Wyoming acquired a new position in shares of AxoGen during the fourth quarter worth about $31,000. Fifth Third Bancorp acquired a new position in shares of AxoGen during the first quarter worth about $92,000. GAMMA Investing LLC boosted its position in shares of AxoGen by 3,884.6% during the first quarter. GAMMA Investing LLC now owns 5,698 shares of the medical equipment provider's stock worth $105,000 after buying an additional 5,555 shares during the period. AlphaQuest LLC boosted its position in shares of AxoGen by 882.2% during the second quarter. AlphaQuest LLC now owns 6,276 shares of the medical equipment provider's stock worth $68,000 after buying an additional 5,637 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of AxoGen during the first quarter worth about $146,000. 80.29% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at AxoGen

In other AxoGen news, Director Joseph A. Tyndall sold 20,062 shares of AxoGen stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $11.20, for a total value of $224,694.40. Following the completion of the transaction, the director owned 15,345 shares in the company, valued at approximately $171,864. The trade was a 56.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 2.78% of the company's stock.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.